

DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

March 18, 2021

MO HealthNet

[Join Webex Meeting](#)

Meeting number (access code): 177 758 8834

Meeting password: PrynQAbQ863

Join from a video system or application

Dial 1777588834@stateofmo.webex.com

You can also dial 173.243.2.68 and enter your meeting number.

[+1-650-479-3207](tel:+16504793207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore
	Old Business	
10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
	New Business	
10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Josh Moore
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	
11:00 – 11:45	Clinical and Fiscal Edits	Josh Moore
	<u>Existing Criteria</u>	
	i. Acne or Rosacea, Select Topical Agents	
	ii. Givlaari	
	iii. Megestrol	
	iv. Sickle Cell Disease	
	v. Systemic Antifungals	
	vi. Zulresso	
	<u>New Criteria or Revision of Existing Criteria</u>	
	i. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators	
	ii. Clobazam Agents	
	iii. Fabry Disease	
	iv. Nocturnal Polyuria	
	v. Opioids, Single Agents Short Acting	
	vi. Oxlumo	
	vii. Spravato	

11:45 – 1:00

Preferred Drug List (PDL)

Josh Moore

Existing Criteria

- i. Actinic Keratosis Agents, Topical
- ii. Antifungals, Oral
- iii. Antihistamines, Intranasal
- iv. Antihistamines/Decongestant Combinations, Second Generation
- v. Antivirals, Oral
- vi. Antivirals, Topical
- vii. Benzoyl Peroxide/Antibiotic Combinations
- viii. Beta Adrenergic Agents, Long Acting
- ix. Beta Adrenergic Agents, Nebulized
- x. Cough/Cold Preparations
- xi. Fluoroquinolones, Ophthalmic
- xii. Mast Cell Stabilizers, Ophthalmic
- xiii. NSAIDs, Ophthalmic
- xiv. Pancreatic Enzymes
- xv. Psoriasis Agents, Oral
- xvi. Psoriasis Agents, Topical
- xvii. Retinoids, Topical
- xviii. Ulcerative Colitis Agents, Rectal

New Criteria or Revision of Existing Criteria

- i. Androgenic Agents
- ii. Antibiotics, Inhaled
- iii. Antifungals, Topical
- iv. Antihistamines, Ophthalmic
- v. Antiparasitics, Topical
- vi. Atopic Dermatitis Agents, Immunomodulators
- vii. Beta Adrenergic Agents, Short Acting
- viii. COPD Agents
- ix. Corticosteroids, Inhaled
- x. Corticosteroids, Intranasal
- xi. Corticosteroids, Ophthalmic Soft
- xii. Corticosteroids, Topical
- xiii. Epinephrine Agents, Self-Injectable
- xiv. Fluoroquinolones, Otic
- xv. Glaucoma Agents
- xvi. Hepatitis C Agents PDL Edit
- xvii. Hereditary Angioedema (HAE) Agents
- xviii. Leukotriene Receptor Modifiers
- xix. Respiratory Monoclonal Antibodies
- xx. Ulcerative Colitis, Oral

1:00 – 1:15

LUNCH

1:15 – 1:30

Program Utilization Information – Conduent Update

Jennifer Colozza

- i. Call Center Statistics
- ii. CyberAccess User Statistics
- iii. New Drug Statistics
- iv. “Top 25” Drugs by Cost/Claims

1:30 – 1:50

Other Business

- i. Sedative Hypnotic PDL Edit Changes Impact Report

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.

NEXT MEETING: June 17, 2021

Meeting via WebEx unless
otherwise specified